This trial will test whether relapsing-remitting MS patients who have not had a relapse in the past year would benefit from switching to ofatumumab, and whether an elevated serum neurofilament light (NfL) level predicts enhanced benefit from ofatumumab.
1 Primary · 16 Secondary · Reporting Duration: Months 3 to 15
Active Control
Experimental Treatment
150 Total Participants · 2 Treatment Groups
Primary Treatment: Ofatumumab · No Placebo Group · Phase 4
Age 18 - 50 · All Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: